Compounders Research Compare

Edesa Biotech, Inc.(EDSA)

Biotechnology · Markham, ON

$3.87-0.04 (-1.15%)

Delayed quote: Oct 6, 2026, 10:38 AM EDT

About Edesa Biotech, Inc.

Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.

Markham, ON

17 employees

www.edesabiotech.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Pardeep Nijhawan

View full financials

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T14:51:50.683Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:51:50.683Z.

Quote observation: 2026-10-06T14:38:49.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 37,232,395
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 10,332,520
TTM operating income · period ending 2026-06-30: -14,628,174

FMP input reference: 4a3a0e03002c1ec33ed026058caacdcc2374dd3411b27b5cd001974e391cfa1f

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

EDSA EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

EDSA Competitors' EV/EBIT Ratio

Edesa Biotech, Inc.

Current

Market Cap

$37.23M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

iTonic Holdings Ltd.

Market Cap

$37.15M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DocGo Inc.

Market Cap

$36.48M

EV/EBIT Ratio

N/A

TTM Avg

8.66x

3Y Avg

44.05x

5Y Avg

43.98x

Elicio Therapeutics, Inc.

Market Cap

$36.13M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Harvard Bioscience, Inc.

Market Cap

$38.52M

EV/EBIT Ratio

74.22x

TTM Avg

60.42x

3Y Avg

123.40x

5Y Avg

130.57x

Incannex Healthcare Limited

Market Cap

$38.71M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Accuray Incorporated

Market Cap

$35.70M

EV/EBIT Ratio

N/A

TTM Avg

50.30x

3Y Avg

467.13x

5Y Avg

265.91x

Nephros, Inc.

Market Cap

$39.63M

EV/EBIT Ratio

21.80x

TTM Avg

36.10x

3Y Avg

319.62x

5Y Avg

319.62x

BriaCell Therapeutics Corp.

Market Cap

$34.80M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Elutia Inc

Market Cap

$34.48M

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Edesa Biotech, Inc. (EDSA)	$37.23M	N/A	N/A	N/A	N/A
iTonic Holdings Ltd. (ITOC)vs ›	$37.15M	N/A	N/A	N/A	N/A
DocGo Inc. (DCGO)vs ›	$36.48M	N/A	8.66x	44.05x	43.98x
Elicio Therapeutics, Inc. (ELTX)vs ›	$36.13M	N/A	N/A	N/A	N/A
Harvard Bioscience, Inc. (HBIO)vs ›	$38.52M	74.22x	60.42x	123.40x	130.57x
Incannex Healthcare Limited (IXHL)vs ›	$38.71M	N/A	N/A	N/A	N/A
Accuray Incorporated (ARAY)vs ›	$35.70M	N/A	50.30x	467.13x	265.91x
Nephros, Inc. (NEPH)vs ›	$39.63M	21.80x	36.10x	319.62x	319.62x
BriaCell Therapeutics Corp. (BCTX)vs ›	$34.80M	N/A	N/A	N/A	N/A
Elutia Inc (ELUT)vs ›	$34.48M	N/A	N/A	N/A	N/A

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA EV/Sales Operating Income All Metrics